Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Novartis Heart Drug Receives FDA Designation to Expedite Review

The Food and Drug Administration has granted Switzerland-based Novartis (NYSE: NVS  ) its "Breakthrough Therapy" (BT) designation for Novartis' acute heart failure (AHF) treatment RLX030 (serelaxin), the company announced today.

According to the FDA, a BT designation is intended to "expedite the development and review of drugs for serious or life-threatening conditions."

The decision came after reviewing evidence including the results of Novartis' Phase 3 RELAX-AHF trial in which there was a 37% reduction in mortality for patients using RLX030 for six months compared to traditional treatments. According to Novartis, RLX030 has the potential to be "the first breakthrough treatment for acute heart failure patients in 20 years."

In response to the FDA's decision, Division Head of Novartis Pharmaceuticals David Epstein was quoted as saying, "Commonly used medicines for AHF only improve the immediate symptoms, so the additional effect on survival observed with RLX030 offers hope to patients and physicians."

RLX030 is the second Novartis treatment to receive the BT designation following LDK 378, a lung cancer medication that was fast-tracked by the FDA.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2503302, ~/Articles/ArticleHandler.aspx, 9/25/2016 10:23:52 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:02 PM
NVS $81.48 Down -0.55 -0.67%
Novartis CAPS Rating: ****